Does NMN really work against aging?

In human studies it consistently raises blood NAD⁺ (+40–80%), but hard clinical endpoints (longevity, disease) are not yet demonstrated. Hence grade B: promising, not conclusive.

What dosage was studied in RCTs?

Main trials use 250–900 mg/day for 8–24 weeks. Higher doses did not show proportionally greater benefits in the available studies.

Short-term, yes: no severe adverse events reported in trials. Long-term safety data are lacking. Always consult a physician before starting.

NMN: What clinical studies really say in 2024

Why NAD⁺ matters in aging

Nicotinamide adenine dinucleotide (NAD⁺) is a central coenzyme in more than 500 enzymatic reactions. With age, tissue NAD⁺ levels decline significantly — a decline documented in preclinical models and in limited human data, not yet precisely quantified in humans. This decline is associated with reduced activity of the sirtuins (SIRT1–7), NAD⁺-dependent enzymes involved in DNA repair, metabolic regulation and the cellular stress response.

NMN (Nicotinamide Mononucleotide) is a direct precursor of NAD⁺ in the salvage synthesis pathway. Unlike niacin and NR, NMN is converted to NAD⁺ after cellular uptake mediated by the Slc12a8 transporter (identified in mouse; the human homolog is under study).

What the clinical trials say

Igarashi et al. 2022 (PMID: 35927255)

The most cited randomized, double-blind human trial enrolled 25 older men (65–80 years) treated with 250 mg/day of NMN for 12 weeks. The main results:

Statistically significant increase in blood NAD⁺ (+38% vs placebo, p<0.01)
Improved gait speed in a subset of subjects with low baseline
No severe adverse events reported

Critical limitation: very small sample size (n=25), surrogate primary outcome (blood NAD⁺, not hard clinical endpoints).

Igarashi M, et al. Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle motility in healthy older men. NPJ Aging. 2022;8(1):5. PMID: 35927255

Yoshino et al. 2021 (PMID: 33888596)

Trial in 25 postmenopausal women with prediabetes, 250 mg/day for 10 weeks. Main result: improved muscle insulin sensitivity (measured with a hyperinsulinemic-euglycemic clamp). The effect was significant only in skeletal muscle, not at the hepatic level.

Yoshino M, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229. PMID: 33888596

Available meta-analyses and systematic reviews

As of 2024 there is no robust meta-analysis on hard clinical endpoints (mortality, chronic-disease incidence). The available reviews agree on: documented short-term safety, replicated surrogate biological efficacy (increased NAD⁺), but insufficient data for strong clinical recommendations.

Dosage and pharmacokinetics

Human trials have used a 100–1200 mg/day range. Oral bioavailability was studied by Irie et al. 2020: plasma peak at 1–2h, short half-life (~2.5h). Sublingual and liposomal formulations show superior absorption in non-RCT studies.

Dosage	NAD⁺ effect	Notes
250 mg/day	+38–45% blood	Most studied
500 mg/day	+50–60% blood	Phase II trials
1000 mg/day	+70–80% blood	Safety confirmed at 12 weeks

Safety

No trial has reported severe adverse events. The most common effects (nausea, flushing) are dose-dependent and rare below 500 mg/day. There are no data on administration beyond 24 months.

Graded verdict

Grade B — Moderate evidence.

NMN is safe in the short term and reliably raises blood NAD⁺. The clinical effect on organ function is biologically plausible but not yet demonstrated in phase III RCTs on hard endpoints. There are no signals of harm, but there is also no definitive case for clinical use. For informed consumers: enough data for reasoned use; for clinicians: not recommendable as standard of care.

FAQ

Is NMN better than NR (nicotinamide riboside)? There is no head-to-head comparison in human RCTs. Mechanistically, NMN is closer to NAD⁺ in the biosynthetic pathway. NR requires one additional phosphorylation step. The practical differences appear marginal.

Should I take it in the morning or evening? Existing studies have not compared timing. Circadian logic (NAD⁺ has diurnal oscillations) suggests the morning, but there are no clinical data to support it.

Does it interact with medications? No interactions are documented in the clinical literature. A theoretical caution exists with anticoagulants (NAD⁺-dependent vitamin K metabolism) — not documented in humans.

Some links in this article are affiliate links. We may receive a commission if you purchase through them, at no extra cost to you. This does not influence our ratings.